Biotech | April 11, 2022
Glenmark Specialty receives DCGI approval for Phase 1 clinical trial of its novel molecule
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
